Does RIBOCICLIB Cause Immune-mediated hepatitis? 5 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Immune-mediated hepatitis have been filed in association with RIBOCICLIB (KISQALI). This represents 0.0% of all adverse event reports for RIBOCICLIB.
5
Reports of Immune-mediated hepatitis with RIBOCICLIB
0.0%
of all RIBOCICLIB reports
2
Deaths
4
Hospitalizations
How Dangerous Is Immune-mediated hepatitis From RIBOCICLIB?
Of the 5 reports, 2 (40.0%) resulted in death, 4 (80.0%) required hospitalization.
Is Immune-mediated hepatitis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RIBOCICLIB. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does RIBOCICLIB Cause?
Neutropenia (3,585)
Nausea (3,404)
Fatigue (3,327)
Malignant neoplasm progression (2,468)
Death (2,452)
Vomiting (1,953)
Diarrhoea (1,830)
White blood cell count decreased (1,683)
Pain (1,637)
Metastases to bone (1,538)
What Other Drugs Cause Immune-mediated hepatitis?
NIVOLUMAB (640)
PEMBROLIZUMAB (549)
IPILIMUMAB (443)
CARBOPLATIN (213)
PACLITAXEL (167)
ATEZOLIZUMAB (142)
BEVACIZUMAB (108)
DURVALUMAB (90)
LENVATINIB (86)
PEMETREXED (86)
Which RIBOCICLIB Alternatives Have Lower Immune-mediated hepatitis Risk?
RIBOCICLIB vs RIBOFLAVIN
RIBOCICLIB vs RIBOFLAVIN 5'-PHOSPHATE
RIBOCICLIB vs RIBOFLAVIN 5^-PHOSPHATE
RIBOCICLIB vs RIFABUTIN
RIBOCICLIB vs RIFAMPICIN